Repositioning Candidate Details
| Candidate ID: | R0686 |
| Source ID: | DB05051 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | BZL101 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in breast cancer. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | BZL101 works by eliciting a cancer cell’s innate mechanism of self-suicide or apoptosis. The drug selectively releases Apoptosis Inducing Factor-1 (AIF1) from a cancer cell’s mitochondrial membrane. AIF then moves to the cell’s nucleus, disintegrating the DNA structure, and fragmenting and killing the cancer cell. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
